Jeffrey Holford

In a report published Tuesday, Jefferies analyst Jeffrey Holford upgraded the rating on Merck  (NYSE: MRK) from Hold to Buy, and raised the price target from $48.00 to $54.00. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of...

In a report published Tuesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), and raised the price target from $90.00 to $97.00. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of...

In a report published Tuesday, Jefferies analyst Jeffrey Holford upgraded the rating on Eli Lilly (NYSE: LLY) from Underperform to Hold, and raised the price target from $44.00 to $49.00. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation...

In a report published Tuesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol Myers Squibb (NYSE: BMY), and raised the price target from $45.00 to $53.50. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of...

In a report published Tuesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), and raised the price target from $51.00 to $54.00. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of undervalued assets...

In a report published Tuesday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Abbott Laboratories (NYSE: ABT), and raised the price target from $43.00 to $46.00. In the report, Jefferies noted, “As the Pharmaceuticals Industry looks towards restructuring and separation of...

Jefferies has initiated coverage of pharma giant and Dow component Pfizer (NYSE: PFE) with a "buy" rating and a $17.80 price target. Analyst Jeffrey Holford said Pfizer's bulk has become a problem for the company's growth prospects and expiring patents, pricing pressure and poor research and...